Saturday, February 12, 2022

New Treatment of Diabetic Retinopathy Showing Positive Outcome

REGENXBIO Inc. announced additional positive interim data from the ongoing Phase II ALTITUDE™ trial of RGX-314 for the treatment of diabetic retinopathy (DR) without center-involved diabetic macular edema (CI-DME) using in-office suprachoroidal delivery. The data is being presented at the Angiogenesis, Exudation, and Degeneration 2022 conference by Michael A. Klufas, M.D., Retina Service, Wills Eye […] - Travel News | eTurboNews | eTN

No comments:

Post a Comment